TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05987696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD33/CLL1 dual CAR-NK cell
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent
Study: NCT04937049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMAeHealth digital tool
Description: eHealth intervention to support Maternal Education
Study: NCT06337903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (the Mindful Self-Compassion course)
Description: An online 8-week mindful self-compassion course with weekly sessions.
Study: NCT04888507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: SC administration
Study: NCT05956782

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathe Easier
Description: See Intervention Group (IG) description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe Easier
Description: See Intervention Group (IG) description.
Study: NCT06130618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
Study: NCT04943627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab (BAL)
Description: Anti-PD-1 Monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Chemotherapy
Study: NCT05987696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD33 CAR-NK cell
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: super NK cell
Description: NK cell therapy
Study: NCT06484816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-1942
Description: At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
Study: NCT05241574

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy boost
Description: Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional consolidation chemotherapy
Description: Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
Study: NCT05769465

Intervention type: DRUG
Intervention: disease modifying treatments
Description: Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec

Intervention type: DRUG
Intervention: disease modifying treatments
Description: Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec

Intervention type: DRUG
Intervention: disease modifying treatments
Description: Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
Study: NCT06160258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready to Eat (RTE)
Description: Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dried
Description: Participants will be provided with dried whole grains for home preparation and consumption
Study: NCT04804579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall Prevention Intervention
Description: The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
Study: NCT05128578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver Education About Pain (LEAP)
Description: LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions.
Study: NCT06466369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: tadalafil 2.5 mg, 5 mg
Study: NCT06472245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE2101
Description: OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGS HLAA2 assay
Description: Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NGS HLAA2 assay
Description: Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.

Intervention type: DEVICE
Group type: OTHER
Intervention: NGS HLAA2 assay
Description: Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
Study: NCT05111548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Active)
Description: tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: BrainHQ
Description: BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
Study: NCT05397080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment VIRTUAL FIBROWALK
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU)~* 4 face-to-face sessions (1 per mounth) Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study: NCT04864067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Consolidation Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoracil
Description: Consolidation Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Consolidation Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Consolidation Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5x5 Gy
Description: Neoadjuvant Radiotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DRE/ Endoscopy
Description: Flexible Sigmoidoscopy and Digital Rectal Exam
Study: NCT06430164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait training: One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds will be delivered without FES.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait training: One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds will be delivered without FES.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Description: Electrical stimulation involving the parameters and settings proposed here is commonly used in clinical practice and research for pain relief and other applications also referred to as neuromuscular or transcutaneous electrical nerve stimulation. The FES will be delivered using the UDel Stimulator, a custom-designed FES system from the University of Delaware FES lab.~Researchers will use a customized, real-time system to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains will be delivered during gait.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation paired with cortical magnetic stimulation pulses
Description: The paired associative stimulation (PAS) will be conducted in a static posture (seated or standing), to evaluate effects on somatosensory, spinal-reflex, and/or corticospinal neurophysiology delivered with different stimulation parameters. One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds may be completed before and/or after PAS to evaluate gait performance
Study: NCT05111548

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (Inactive)
Description: tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
Study: NCT06036485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis Omega 3
Description: Decellularized intact fish skin developed for the management of chronic wounds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical debridement
Description: Superficial sharp surgical debridement technique
Study: NCT05161247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zona pellucida sperm selection
Description: Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sperm selection
Description: Sperm selection for ICSI based on the sperm morphology.
Study: NCT05813457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRESTO Early Identification Program
Description: The program combines :~1. A population-based information component (information campaign aimed at the general population).~2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~3. Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)
Study: NCT05161247

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic Sperm Injection (ICSI)
Description: Normal ICSI procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic Sperm Injection (ICSI)
Description: Normal ICSI procedure.
Study: NCT05701020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnary
Description: If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
Study: NCT04597385

Intervention type: OTHER
Intervention: Long-term Follow-Up
Description: No intervention
Study: NCT04920578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69095897
Description: JNJ-69095897 will be administered orally in Parts 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69095897
Description: JNJ-69095897 will be administered orally in Parts 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69095897
Description: JNJ-69095897 will be administered orally in Parts 1, 2 and 3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered orally in Parts 1 and 3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered orally in Parts 1 and 3.
Study: NCT04912726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Injectable Product
Description: The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
Study: NCT04276857

Intervention type: DEVICE
Group type: OTHER
Intervention: Irreversible electroporation (NanoKnife® )
Description: IRE is a unique treatment modality as it ablates tumor cells without using heat or radiation and hence does not cause injury to nearby blood vessels, ducts, and bowel. This makes it particularly appealing for the treatment of locally advanced unresectable pancreatic cancers. This local treatment for cancer involves delivering brief pulses of high voltage electrical current across the tumor (either percutaneously or open surgery), which results in the formation of tiny holes (nanopores) in the cell membranes.
Study: NCT05485415

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal intervention
Description: Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
Study: NCT04800848

Intervention type: DEVICE
Intervention: Mask
Description: Physical Fitness is evaluated with the use of a face mask
Study: NCT05727735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Signia Stapler
Description: The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling
Description: The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
Study: NCT05246371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol, dexmedetomidine
Description: Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
Study: NCT05485415

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General sleep advice
Study: NCT05246371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Patients will receive maintenance of general anesthesia by desflurane.
Study: NCT05902598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSA001 injection
Description: also referred to as ARO-APOC3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSA001 injection
Description: also referred to as ARO-APOC3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching VSA001 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching VSA001 injection
Study: NCT06263816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental group: Patients will be treated with carvedilol.
Description: Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group: Patients will receive a placebo.
Description: Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
Study: NCT05546476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponsegromab
Description: Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponsegromab
Description: Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponsegromab
Description: Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ponsegromab
Description: Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
Study: NCT04522596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Umeclidinium/vilanterol 55/22 μg inhaled once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled once a day
Study: NCT05149534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Narrative written disclosure of trauma administered in an evidence-based protocol.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Written Exposure Therapy
Description: Narrative written disclosure of trauma administered in an evidence-based protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Noninvasive magnetic neuromodulation device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Noninvasive magnetic neuromodulation device
Study: NCT06042634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychoeducation
Description: Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face psychoeducation
Description: Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
Study: NCT05629260

Intervention type: DRUG
Intervention: ATG
Description: Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.

Intervention type: DRUG
Intervention: Post-transplantation cyclophosphamide
Description: Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
Study: NCT06152666

Intervention type: OTHER
Intervention: None - qualitative interviews
Description: These are qualitative interviews and involve no intervention